Enlarge image
Company logo in front of the Biontech headquarters in Mainz
Photo: Andreas Arnold / dpa
The financial effect in Germany is likely to be around 16 billion euros by 2030 thanks to the business with corona vaccines.
This is the conclusion of a previously unpublished study commissioned by the Association of Research-Based Drug Manufacturers (VfA).
This goes hand in hand with a large number of jobs.
An estimated 57,000 years of employment are likely to result from vaccine production in Germany over the next eight years.
According to the lobby study, the pharmaceutical industry in Germany also proved to be crisis-proof in other respects.
Compared to other sectors of the German economy, the pharmaceutical industry was not affected by any economic downturn during the pandemic years, according to the analysis.
There were also almost no supply chain breaks in this area in this country.
Due to the Comirnaty vaccine, which was significantly developed by the Mainz-based company Biontech, money in the upper double-digit billion range flowed into the local location from license income alone and ensured economic growth.
In 2021, the pharmaceutical industry in Germany directly and indirectly generated gross value added of around 33.6 billion euros, gave work to a good 278,000 people and generated tax revenue of 11.7 billion euros, according to the study.
Influence of location has diminished
Despite these jubilant numbers, the German pharmaceutical industry is no longer as relevant as it used to be.
Companies that used to be important have either merged or disappeared, and other countries have mostly taken on the role of the former »pharmacy of the world«.
The lobby association sees great hope for the future through the mRNA technology on which Biontech's Covid 19 vaccine is based.
Both in the development of drugs based on it, for example in oncology, and in their manufacture, there is "enormous economic growth potential".
